Search results for: juvenile idiopathic arthritis

Biosimilars Update: FDA Panel Voted to Approve Biosimilars for Etanercept & Adalimumab at July Meeting

Michele B. Kaufman, PharmD, BCGP | July 15, 2016

In July, the FDA’s Arthritis Advisory Committee will meet and review proposed biosimilars for etanercept and adalimumab to treat multiple rheumatic diseases…

FDA Panel Supports Novartis Biosimilar of Etanercept

Reuters Staff | July 14, 2016

(Reuters)—Novartis AG’s cheaper version of Amgen Inc.’s arthritis drug etanercept (Enbrel) is highly similar in potency and safety to the original and should be approved, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The panel voted 20–0 that there is no clinically meaningful difference between Novartis’s drug, a biologic made…

The Microbiome in Pediatric Rheumatic Diseases

Matthew Stoll, MD, PhD | April 15, 2016

The human intestinal microbiota is home to more than 1,000 bacterial species, containing approximately 3 million genes, many of which code for functions that have the potential to affect human physiology.1 Smaller numbers of organisms are also present in the skin, upper gastrointestinal tract, female reproductive tract and the oro- and nasopharynx. As tools have…

Opioid Investigated to Treat Acute & Chronic OA Pain; Plus New RA Treatment & More

Michele B. Kaufman, PharmD, BCGP | January 20, 2016

In Phase 2 trials, the oral opioid, CR845, has proved promising in treating pain in patients with hip and knee osteoarthritis. Olokizumab is being investigated to treat RA, and in Canada, adalimumab has been approved to treat polyarticular JIA in 2–4 year-olds…

Disease Duration, Corticosteroid Use Predict Etanercept Response in JIA

Reuters Staff | January 16, 2016

NEW YORK (Reuters Health)—Almost half of juvenile idiopathic arthritis (JIA) patients treated with etanercept achieve minimal disease activity after one year of treatment, according to new findings. Younger patients and those who did not require corticosteroid treatment were more likely to have an excellent response, Dr. Kimme Hyrich of the University of Manchester in the…

Air Pollution: Is There an Association with Rheumatic Disease?

Gavin R. Sun, MD, Sasha Bernatsky, MD, Gilaad G. Kaplan, MD, & Cheryl Barnabe, MD | December 17, 2015

Interactions between an individual’s genetic background and their exposure to environmental factors are thought to result in a cascade of immune reactions, ultimately leading to the development of autoimmune diseases such as rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), systemic lupus erythematosus (SLE) and juvenile dermatomyositis.1,2 For example, an environmental factor that conclusively affects susceptibility…

Rituximab May Benefit Patients with Refractory JIA-Associated Uveitis

Lorraine L. Janeczko | October 21, 2015

NEW YORK (Reuters Health)—Rituximab may calm juvenile idiopathic arthritis (JIA)-associated uveitis and especially benefit patients who haven’t responded to other biologic treatments, a study from Italy suggests. With its convenient dosing schedule, rituximab may be a new treatment option for patients with autoimmune diseases, especially for those who have not responded to tumor necrosis factor…

Celiac Disease in Pediatric Patients

Richard Quinn | October 21, 2015

A retrospective study shows that some patients presenting for pediatric rheumatology evaluation test positive for celiac disease—some without showing any gastrointestinal manifestations. Treatment includes a gluten-free diet…

Interdisciplinary Collaboration at Wash U Advances Understanding of Immunology, Rheumatology

Gretchen Henkel | October 14, 2015

In June 2014, 10 members of a church group returned to St. Louis from Haiti, where they had contracted chikungunya virus (CHIKV), a mosquito-transmitted alphavirus previously unknown in the Western hemisphere that produces inflammatory arthritis symptoms. Because CHIKV-related arthritis mimics seronegative RA, a group of clinicians, immunologists, virologists and geneticists at the Washington University in…

2015 ACR/ARHP Annual Meeting to Offer Clinical Focus Course

Maura Iversen | September 15, 2015

Want to hear about the latest advances in rheumatoid arthritis (RA), osteoarthritis (OA), systemic lupus erythematosus (SLE) and polymyositis/dermatomyositis and how best to implement interprofessional care for your patients? The Association of Rheumatology Health Professionals (ARHP) Clinical Focus Course (CFC) is the course for you. The CFC is a full-day course titled, Clinical Advances in…